Valuation: Proteome Sciences plc

Market Cap 6.66M 8.96M 7.83M 7.23M 12.57M 863M 12.84M 86.47M 33.98M 423M 33.64M 32.92M 1.46B P/E 2024
-2.95x
P/E 2025 -2.4x
Enterprise Value 21.65M 29.13M 25.45M 23.51M 40.84M 2.8B 41.72M 281M 110M 1.37B 109M 107M 4.73B EV / Sales 2024
4.79x
EV / Sales 2025 5.96x
Free-Float
81.91%
Yield 2024 *
-
Yield 2025 -
1 day-18.14%
Current month-18.15%
1 month-18.15%
3 months-18.15%
6 months-47.00%
Current year-47.00%
1 month 0.02
Extreme 0.02026
0.02
Current year 0.02
Extreme 0.02026
0.02
1 year 0.01
Extreme 0.0133
0.05
3 years 0.01
Extreme 0.0133
0.09
5 years 0.01
Extreme 0.0133
0.18
10 years 0.01
Extreme 0.0133
0.23
Manager TitleAgeSince
Corporate Officer/Principal - 2017-03-31
Corporate Secretary - 2017-07-31
Director TitleAgeSince
Chairman 73 2014-06-29
Director/Board Member 62 2009-12-31
Director/Board Member 71 2014-06-30
Change 5-day change 1-year change 3-year change Capi.($)
-18.14%0.00% - - 9.22M
+1.87%+6.65%-23.58%-6.72% 172B
-0.43%+0.98%-7.33%-5.08% 107B
-0.03%+1.80%+3.38%+60.85% 59.92B
-1.10%+4.85%-11.28%-39.02% 44.07B
-3.21%-2.59% - - 34.76B
-1.71%+4.97%-8.89%-44.18% 30.09B
-1.16%+0.16%+59.66%-6.98% 25.61B
-0.91%+3.40%-4.45%-19.40% 20.86B
-1.49%+0.85%-4.30%-4.91% 21.55B
Average -2.85%+3.27%+0.40%-8.18% 57.33B
Weighted average by Cap. -0.77%+3.37%-8.44%-3.72%

Financials

2024 2025
Net sales 4.89M 6.57M 5.75M 5.31M 9.22M 633M 9.42M 63.42M 24.92M 310M 24.67M 24.15M 1.07B 3.76M 5.05M 4.42M 4.08M 7.08M 486M 7.24M 48.74M 19.15M 238M 18.96M 18.56M 821M
Net income -3.41M -4.58M -4M -3.7M -6.42M -441M -6.56M -44.2M -17.37M -216M -17.19M -16.83M -744M -3.06M -4.12M -3.6M -3.32M -5.77M -396M -5.9M -39.72M -15.61M -194M -15.45M -15.12M -669M
Net Debt 13.39M 18.02M 15.75M 14.54M 25.26M 1.73B 25.81M 174M 68.29M 850M 67.61M 66.18M 2.93B 14.99M 20.16M 17.62M 16.27M 28.27M 1.94B 28.88M 195M 76.42M 951M 75.66M 74.06M 3.27B
Logo Proteome Sciences plc
Proteome Sciences plc is a specialist provider of contract proteomics services. The Company’s services enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. Its principal activities involve protein biomarker research and development. It uses high-sensitivity techniques to detect and characterize differentially expressed proteins in biological samples for diagnostic, prognostic and therapeutic applications. SysQuant and TMT MS2 are unbiased methods for identifying and contextualizing new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. In addition, it has invented and developed the technology for TMT and TMTpro, and manufactures these small, protein-reactive chemical reagents for multiplex quantitative proteomics.
Employees
32
Date Price Change Volume